| Wang, Nan |
NCT06475417: Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer |
|
|
| Recruiting | 2 | 42 | RoW | Adebrelimab combined with DOS | Tang-Du Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Gastric Cancer | 05/25 | 04/26 | | |
| Jiang, Tao |
NCT04934059: Efficacy and Safety of Yuxuebi Tablet in Treating Night Pain of Ankylosing Spondylitis (AS). |
|
|
| Not yet recruiting | 4 | 60 | RoW | Yuxuebi tablet, Placebo tablet | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. | Ankylosing Spondylitis | 01/22 | 01/22 | | |
NCT05188989: Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction. |
|
|
| Completed | 3 | 765 | RoW | TPN171H 2.5mg group, Simmerafil, TPN171H 5mg group, TPN171H 10mg group, Placebo group | Vigonvita Life Sciences | Erectile Dysfunction | 02/23 | 02/23 | | |
NCT06301854: Long-term Safety of TPN171H Tablet in Erectile Dysfunction. |
|
|
| Recruiting | 3 | 472 | RoW | TPN171H, Simmerafil | Vigonvita Life Sciences | Erectile Dysfunction | 04/25 | 04/25 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
NCT05388825: Pharmacodynamic Study of TPN171H Tablets in Patients With Mild to Moderate Erectile Dysfunction |
|
|
| Completed | 2 | 84 | RoW | TPN171H 2.5mg, TPN171H 5mg, TPN171H 10mg, Placebo 5mg, Placebo 10mg | Vigonvita Life Sciences | Erectile Dysfunction | 01/23 | 02/23 | | |
NCT05247216: A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis |
|
|
| Completed | 2 | 140 | RoW | Hemay007 800 mg QD group, Hemay007 1200 mg QD group, Hemay007 600 mg QD group, Hemay007 placebo group | Tianjin Hemay Pharmaceutical Co., Ltd | Rheumatoid Arthritis | 06/23 | 06/23 | | |
NCT06451640: A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps |
|
|
| Recruiting | 2 | 60 | RoW | 210mg of TQC2731 injection, 420mg of TQC2731 injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Chronic Rhinosinusitis With Nasal Polyps | 05/25 | 02/26 | | |
NCT06036927: A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal Polyps |
|
|
| Recruiting | 2 | 80 | RoW | TQC2731 injection, TQC2731 matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Sinusitis, Nasal Polyps | 07/25 | 09/25 | | |
NCT05577091: Tris-CAR-T Cell Therapy for Recurrent Glioblastoma |
|
|
| Recruiting | 1 | 10 | RoW | Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes., Autologous Tris-CAR-T cell. | Beijing Tiantan Hospital, Beijing Neurosurgical Institute, Tasly Pharmaceutical Group Co., Ltd | Recurrent Glioblastoma | 11/24 | 11/32 | | |
| Min, Jie |
NCT06475209: Adebrelimab + Apatinib in SCLC Maintenance Therapy |
|
|
| Recruiting | 2 | 60 | RoW | Adebrelimab combined with Apatinib | Tang-Du Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd. | SCLC | 12/25 | 12/26 | | |
| yan, xiaolong |
| No trials found |
